Shaily Engineering Plastics Limited (SHAILY)
📢 Recent Corporate Announcements
Shaily Engineering Plastics Limited has issued the notice for its 46th Annual General Meeting scheduled for September 28, 2026. The key agenda items include an enabling special resolution to raise up to Rs 500 crore through equity or convertible instruments, representing ~77% of its Rs 649 crore net worth. Shareholders will also vote on a final dividend of Rs 3 per equity share (150% of face value Rs 2) for FY26. Additionally, the AGM agenda covers the re-appointment of Managing Director Amit Mahendra Sanghvi for 5 years and a revised remuneration package for Kinjal Bhavsar, Managing Director of its UK subsidiary.
- Enabling resolution to raise funds up to Rs 500 crore via QIP, preferential issue, rights issue, or convertible securities
- Recommendation of Rs 3 per equity share (150% of face value Rs 2) dividend for FY26
- Re-appointment of Amit Mahendra Sanghvi as Managing Director for 5 years effective October 1, 2026 (drawing no remuneration from the parent company)
- Approval of remuneration for Kinjal Bhavsar, MD of UK subsidiary, at basic salary of GBP 240,000 p.a. plus GBP 12,000 p.m. HRA
Shaily Engineering Plastics Limited has scheduled an analyst and institutional investor group meeting on August 21, 2026, starting at 10:00 AM IST in Baroda, Gujarat. The company confirmed that interactions will be limited to publicly available information with no unpublished price-sensitive information (UPSI) disclosed. This filing is an administrative disclosure under Regulation 30(6) of SEBI LODR Regulations.
- Meeting date scheduled for 21st August 2026
- Meeting start time: 10:00 AM onwards
- Format: Group Meeting
- Venue: Baroda, Gujarat
- Discussions restricted strictly to non-UPSI publicly available information
Shaily Engineering Plastics released its Q1 FY27 earnings call transcript, highlighting a 14% YoY increase in consolidated revenue to ₹281 crore and an 18% YoY rise in EBITDA to ₹83 crore (29.7% margin). Growth was driven by the Healthcare division, which jumped 85% YoY to ₹142 crore and now accounts for 51% of total revenue. The company is set to commission an additional 25 million pen capacity by September 2026, expanding total annual pen capacity to approximately 75 million pens. Meanwhile, the Consumer segment fell 24% YoY to ₹116 crore due to sluggish export demand in the US and Europe.
- Healthcare revenue grew 85% YoY to ₹142 crore, contributing 51% of consolidated Q1 FY27 revenue.
- Consolidated revenue stood at ₹281 crore (+14% YoY) with PAT rising 17% YoY to ₹48 crore (PAT margin of 17.1%).
- Additional 25 million pen injector capacity on track for operationalization by end of September 2026, reaching ~75 million pens per annum.
- Consumer segment revenue dropped 24% YoY to ₹116 crore amid soft demand in home furnishings in the US and Europe.
- Targeting completion of emergency auto-injector program by end-FY27 and Abu Dhabi plant production by end-FY28.
Shaily Engineering Plastics has made the audio recording of its earnings call held on August 10, 2026, available to the public. This follows the company's recent financial performance, which shows a TTM revenue of Rs 977 Cr and a robust operating margin of 28.4%. The call likely covers the company's strategic shift toward high-margin healthcare products, which saw 171% growth in H1 FY26. A written transcript is expected to follow as per regulatory requirements.
- Earnings call conducted on August 10, 2026, following quarterly results.
- Audio recording uploaded to the company's website under the investor compliance section.
- Company maintains a high TTM PAT of Rs 168 Cr with a 30% ROCE.
- Management previously guided for a 36% growth rate driven by IP-led healthcare platforms.
- Promoter holding stands at 41.09% as of June 2026.
Shaily Engineering Plastics has approved the re-appointment of Mr. Amit Mahendra Sanghvi as Managing Director for a five-year term effective October 1, 2026. The board also fixed September 11, 2026, as the record date for the final dividend of FY 2025-26. These decisions come alongside the approval of Q1 FY27 financial results. With a TTM revenue of ₹977 Cr and a strong ROCE of 30%, leadership continuity is vital for the company's stated 36% growth target driven by the healthcare segment.
- Re-appointment of Amit Mahendra Sanghvi as MD for a 5-year term until September 30, 2031
- Fixed September 11, 2026, as the Record Date for the FY 2025-26 final dividend
- Board meeting concluded after 3 hours and 5 minutes of deliberation on August 8, 2026
- Company maintains a high Operating Profit Margin (OPM) of 28.4% as per TTM data
- Promoter holding remains stable at approximately 41.1% as of June 2026
Shaily Engineering Plastics reported a 14% YoY revenue growth to ₹280.7 Cr for Q1 FY27, primarily driven by a massive 85% surge in the Healthcare segment (₹142.4 Cr). Despite a 24% decline in the Consumer business due to weak demand in Western markets, consolidated EBITDA margins improved by 120 bps to 29.7%. Net profit rose 17% YoY to ₹48.0 Cr. The company secured new projects across FMCG, LED, and Automotive sectors, and received key approvals for Semaglutide pens in Canada and Brazil.
- Healthcare segment revenue grew 85% YoY to ₹142.4 Cr, now contributing over 50% of total revenue.
- Consolidated EBITDA margins expanded to 29.7% from 28.5% in the previous year's quarter.
- Consumer business revenue declined 24% YoY to ₹115.5 Cr due to weak home furnishing demand in Europe and USA.
- Annualized ROCE improved to 39.0% as of June 2026 compared to 35.8% in March 2026.
- Received customer approvals for Semaglutide pens in Canada and Brazil, with two new IP-led platform projects signed.
Shaily Engineering Plastics has fixed September 11, 2026, as the record date for its final dividend for FY 2025-26. The board also approved the re-appointment of Mr. Amit Mahendra Sanghvi as Managing Director for a five-year term effective October 1, 2026. These decisions follow a strong financial performance in FY26, where the company reported a PAT of ₹168 Cr, an 80% increase over FY25. The company continues to focus on its high-margin healthcare segment, which has been a primary growth driver.
- Record date for final dividend for FY 2025-26 fixed as September 11, 2026
- Managing Director Amit Mahendra Sanghvi re-appointed for a 5-year term until September 30, 2031
- Board approved unaudited standalone and consolidated financial results for Q1 FY27
- Promoter holding stands at 41.09% as of June 2026, down from 43.39% in March 2026
- Company maintains a high OPM of 28.4% and ROCE of 30.0% based on TTM data
Shaily Engineering Plastics reported a steady Q1 FY27 with consolidated revenue growing 22.1% YoY to ₹274.78 cr. Consolidated net profit increased by 16.7% YoY to ₹48.01 cr, supported by strong standalone performance where PBT rose to ₹70.40 cr. The board confirmed the re-appointment of Managing Director Amit Sanghvi for a five-year term (2026-2031) and set September 11, 2026, as the record date for the final dividend.
- Consolidated revenue from operations rose to ₹274.78 cr in Q1 FY27 from ₹225.10 cr in Q1 FY26.
- Consolidated net profit grew to ₹48.01 cr, up from ₹41.12 cr in the corresponding quarter last year.
- Standalone Profit Before Tax (PBT) showed significant strength at ₹70.40 cr vs ₹48.25 cr YoY.
- Managing Director Amit Mahendra Sanghvi re-appointed for a 5-year term effective October 1, 2026.
- Record date for final dividend for FY 2025-26 fixed as Friday, September 11, 2026.
Shaily Engineering Plastics reported a strong start to FY27 with standalone revenue growing 22.1% YoY to ₹274.78 Cr. Standalone Net Profit saw a significant jump of 46.1% YoY to ₹52.47 Cr, reflecting improved operational efficiencies. The Board has re-appointed Mr. Amit Mahendra Sanghvi as Managing Director for a five-year term effective October 2026, ensuring leadership continuity. Additionally, September 11, 2026, has been fixed as the record date for the final dividend of FY 2025-26.
- Standalone Revenue from operations increased 22.1% YoY to ₹274.78 Cr from ₹225.10 Cr.
- Standalone Net Profit surged 46.1% YoY to ₹52.47 Cr compared to ₹35.91 Cr in the previous year's quarter.
- MD Amit Mahendra Sanghvi re-appointed for a 5-year term from October 1, 2026, to September 30, 2031.
- Fixed September 11, 2026, as the Record Date for the final dividend for FY 2025-26.
- Allotted 40,155 equity shares of ₹2 each under the ESOP Plan 2019 during the quarter.
Shaily Engineering Plastics has submitted its quarterly compliance certificate for the period ended June 30, 2026, as required under SEBI (Depositories and Participants) Regulations. The filing confirms that the company's Registrar and Share Transfer Agent, Bigshare Services Private Limited, processed all dematerialization requests within the mandated 15-day window. This process involves the mutilation of physical certificates and updating the depository as the registered owner. This is a standard administrative filing and does not impact the company's financial performance or business operations.
- Quarter ended: June 30, 2026
- Processing window: Within 15 days of receipt of certificates
- Registrar: Bigshare Services Private Limited
- Regulation: 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Shaily Engineering Plastics has scheduled a two-day investor roadshow in London, UK, on July 13th and 14th, 2026. The meetings, organized by UBS, will include 1x1 and group interactions with institutional investors. These discussions will be limited to publicly available information. This outreach occurs as the company maintains a high P/E of 79.1 and a strong TTM revenue of Rs 977 Cr, driven by its rapidly growing healthcare segment.
- Two-day investor interaction scheduled for July 13th and 14th, 2026
- Meetings to be held in London, UK, organized by UBS
- Daily interaction window of 8 hours from 10:00 AM to 6:00 PM
- Company currently operates with a high OPM of 28.4% and ROCE of 30.0%
Shaily Engineering Plastics Limited has announced the closure of its trading window starting July 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The window will remain closed for all designated persons until 48 hours after the results are made public. The specific date for the board meeting to approve these results is yet to be announced.
- Trading window closure begins effective Wednesday, July 01, 2026.
- Closure is related to the Unaudited Financial Results for the quarter ending June 30, 2026.
- The window will reopen 48 hours after the official declaration of financial results.
- The date for the Board Meeting to approve results will be communicated in a separate filing.
Shaily Engineering Plastics Limited has scheduled an interaction with institutional investors and analysts on June 16, 2026. The event is organized by Systematix and will be held at Taj Santacruz, Mumbai, between 10:00 AM and 6:00 PM. The meetings will be conducted in 1x1 and group formats, focusing on publicly available information. The company has clarified that no unpublished price sensitive information (UPSI) will be discussed during these interactions.
- Investor meeting scheduled for June 16, 2026, in Mumbai.
- Organized by Systematix featuring 1x1 and group meeting formats.
- Full-day engagement window from 10:00 AM to 6:00 PM.
- Compliance filing under Regulation 30(6) of SEBI LODR Regulations 2015.
Shaily Engineering Plastics reported a robust FY26 with consolidated revenue growing 26% to ₹991 crores and PAT rising 83% to ₹170 crores. The Healthcare segment was the primary driver, with revenue surging 139% to ₹393 crores, now contributing 40% of the total mix. While the Consumer segment saw a 9% decline due to weak global demand in home furnishings, EBITDA margins expanded significantly by 630 bps to 29.0%. The company achieved major milestones including the launch of Semaglutide pen injectors in Canada and entry into the semiconductor tray market.
- FY26 PAT grew 83% YoY to ₹170 crores with EBITDA margins expanding to 29.0%.
- Healthcare revenue surged 139% to ₹393 crores, driven by the commercial launch of Semaglutide pen injectors.
- Achieved first tentative U.S. approval for Semaglutide pens and European authorization for Teriparatide.
- Diversified into semiconductor supply chain via a supply agreement with a Korean company for precision trays.
- Board approved an enabling resolution to raise up to ₹500 crores to maintain capital agility for future growth.
Shaily Engineering Plastics Limited has announced a group meeting with analysts and institutional investors scheduled for May 30, 2026, in Baroda, Gujarat. The meeting is set to begin at 10:00 AM and will focus on discussions regarding the company's performance based on publicly available information. As per the regulatory filing, no unpublished price sensitive information (UPSI) is intended to be discussed. This interaction is a standard procedure to engage with the investment community and maintain transparency.
- Group meeting with analysts and institutional investors scheduled for May 30, 2026.
- The meeting is set to commence at 10:00 AM onwards in Baroda, Gujarat.
- Discussions will be strictly limited to publicly available information with no UPSI disclosure.
- The disclosure is made under Regulation 30(6) of the SEBI (LODR) Regulations, 2015.
Financial Performance
Revenue Growth by Segment
In H1 FY26, the Pharma segment grew 171% YoY to INR 176 Cr, the Industrial segment grew 17% YoY to INR 41 Cr, and the Consumer segment grew 6% YoY to INR 286 Cr. Overall consolidated revenue for H1 FY26 grew 36% YoY to INR 503.3 Cr.
Geographic Revenue Split
The UK-based subsidiary, Shaily Innovations Limited, reported a turnover of INR 48.68 Cr (GBP based) for FY25, representing approximately 6% of consolidated revenue. The company also expanded into Dubai with Shaily Innovations FZCO in January 2025.
Profitability Margins
Consolidated PAT margins improved significantly from 10.6% in H1 FY25 to 18.4% in H1 FY26. Gross profit margins on a standalone basis improved from 40.6% to 53.0% (+1,230 bps) in the same period due to a shift toward higher-margin IP-led pen platforms.
EBITDA Margin
Consolidated EBITDA margin stood at 30.2% in H1 FY26, an increase of 930 bps over 20.9% in H1 FY25. EBITDA grew 96% YoY to INR 152 Cr.
Capital Expenditure
Net cash used in investing activities (primarily capex) was INR 87.5 Cr in H1 FY26 compared to INR 19.2 Cr in H1 FY25. The company is committing to new capacities to support healthcare segment growth.
Credit Rating & Borrowing
CARE Ratings reaffirmed CARE A+; Stable for long-term bank facilities (INR 239.62 Cr) and CARE A1 for short-term facilities (INR 35.00 Cr) in October 2025. Borrowing costs are reflected in a finance cost of INR 7.8 Cr for H1 FY26.
Operational Drivers
Raw Materials
Plastic resins and polymers (common materials used across all platforms) represent the primary raw material cost, which accounted for approximately 47% of standalone revenue in H1 FY26 (INR 216.7 Cr).
Import Sources
Not disclosed in available documents, though the company notes vulnerability to exchange rate fluctuations, implying significant imports.
Capacity Expansion
The fixed asset turnover ratio stands at 2x as of September 30, 2025. The company has committed to new capacities specifically for the healthcare segment to meet increased demand for drug delivery devices.
Raw Material Costs
Raw material and purchase costs stood at INR 216.7 Cr for H1 FY26. Profitability is vulnerable to raw material price volatility, though commonality of materials across platforms allows for supply chain flexibility.
Manufacturing Efficiency
EBITDA margins of 30.2% and a fixed asset turnover of 2x reflect high efficiency in precision moulding operations.
Strategic Growth
Expected Growth Rate
36%
Growth Strategy
Growth is driven by scaling the healthcare segment, which grew 171% in H1 FY26. Strategy includes commercializing IP-led pen platforms, executing new collaborative design-to-manufacture contracts with MNC pharma companies, and expanding design services through the Dubai subsidiary.
Products & Services
Drug delivery devices (insulin pens), precision plastic components for consumer electronics, and industrial plastic packaging.
Brand Portfolio
Shaily
New Products/Services
IP-led pen platforms and new drug delivery device contracts are expected to start commercial supplies in H2 FY26.
Market Expansion
Expansion into the Middle East via Shaily Innovations FZCO (Dubai) for drug delivery device design and development.
Strategic Alliances
Collaborative design-to-manufacture contracts with multinational pharmaceutical companies for precision moulding.
External Factors
Industry Trends
The industry is shifting toward precision-engineered plastics in healthcare. Shaily is positioned to benefit from this as healthcare revenue share doubled to 38% in Q2 FY26.
Competitive Landscape
Competes in the precision plastic injection moulding space, serving global leaders in pharma and consumer segments.
Competitive Moat
Moat is built on IP-led pen platforms, 40 years of promoter experience in injection moulding, and established relationships with global MNCs. These are sustainable due to high switching costs in regulated pharma markets.
Macro Economic Sensitivity
Highly sensitive to exchange rate fluctuations and global polymer price volatility.
Consumer Behavior
Increased demand for self-administration drug delivery devices is driving the 171% growth in the healthcare segment.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent medical device manufacturing standards and drug delivery device contract regulations.
Taxation Policy Impact
The effective tax rate for H1 FY26 was approximately 23.5% (INR 28.4 Cr tax on INR 120.8 Cr PBT).
Legal Contingencies
Not disclosed in available documents; MDA reports no material contracts or arrangements with related parties that were not at arm's length.
Risk Analysis
Key Uncertainties
Regulatory approval delays for new pharma platforms (potential 12-14 month impact) and raw material price volatility.
Geographic Concentration Risk
Manufacturing is concentrated in India, while R&D and design are spread across the UK and Dubai.
Third Party Dependencies
High dependency on a few large-size multinational customers for a majority of revenue.
Technology Obsolescence Risk
Mitigated by continuous investment in R&D centers in the UK and Dubai to develop next-generation drug delivery platforms.
Credit & Counterparty Risk
Maintains a healthy financial profile with adequate liquidity and a CARE A+ credit rating.
